Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.

ABSTRACT:

Background

Comparisons of second-line anti-tumour necrosis factor (TNF) agents and vedolizumab are sparse.

Aim

To evaluate the effectiveness of anti-TNF agents compared to vedolizumab as second-line biologics in inflammatory bowel disease (IBD).

Methods

A propensity score-matched cohort was created using Swedish nationwide registers. Patients with Crohn's disease or ulcerative colitis, exposed to first-line anti-TNF treatment, who initiated a second anti-TNF agent or vedolizumab in 2014-2016 (N = 1363) were included. The primary outcome was drug survival at 12 months. Secondarily, we assessed survival without IBD-related hospitalisation, IBD-related surgery, antibiotics, or hospitalisation because of infection, and also corticosteroid exposure.

Results

After 1:

SUBMITTER: Rundquist S 

PROVIDER: S-EPMC7898922 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature